Evidence map›Paper›PMID 41235252›Full record

ArticleFrontiers in immunology2025

Integrating scRNA-seq and machine learning identifies MNAT1 as a therapeutic target in OSCC.

Han Gao, Lehua Liu, Weixiang Qian, Yanfei Wu, Jiayao Wang, Weiping Yang, Yinfang Shi

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Han Gao *Department of Stomatology, First Affiliated Hospital of Huzhou University, The First People's Hospital of Huzhou, Huzhou, Zhejiang, China.
Lehua Liu *Department of Stomatology, First Affiliated Hospital of Huzhou University, The First People's Hospital of Huzhou, Huzhou, Zhejiang, China.
Weixiang QianDepartment of Stomatology, First Affiliated Hospital of Huzhou University, The First People's Hospital of Huzhou, Huzhou, Zhejiang, China.
Yanfei WuDepartment of Stomatology, First Affiliated Hospital of Huzhou University, The First People's Hospital of Huzhou, Huzhou, Zhejiang, China.
Jiayao WangDepartment of Stomatology, First Affiliated Hospital of Huzhou University, The First People's Hospital of Huzhou, Huzhou, Zhejiang, China.
Weiping YangDepartment of Stomatology, First Affiliated Hospital of Huzhou University, The First People's Hospital of Huzhou, Huzhou, Zhejiang, China.
Yinfang ShiDepartment of Stomatology, First Affiliated Hospital of Huzhou University, The First People's Hospital of Huzhou, Huzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Oral squamous cell carcinoma, with high global incidence and mortality, requires improved early intervention strategies. Ubiquitination - a critical post-translational modification - has been strongly implicated in tumorigenesis, with particularly significant roles in T-cell regulation. We developed a T Cell-Related ubiquitination risk model that enhances prognostic prediction and immunotherapy response assessment, offering a framework for personalized OSCC manageme. Method: T cell-Related Ubiquitination genes were identified based on scRNA-seq analysis, and key genes were selected using WGCNA and LASSO algorithms to construct a prognostic model. Spearman correlation analysis revealed significant associations between riskScore and immune infiltration levels, checkpoint molecule expression, and MMR activity. Pseudotemporal trajectory and cell-cell communication analyses delineated dynamic gene expression patterns driving OSCC progression. Functional validation through colony formation and Transwell assays confirmed the tumor-suppressive effects of key model genes. Results: Given the high correlation between T cell-Related Ubiquitination genes and the prognosis of OSCC patients, a prognostic model based on patient scRNA-seq data was constructed and validated. The RiskScore derived from our model correlated significantly with expression levels of MMR genes, abundance of immune checkpoint proteins, and immunotherapy response. Cell-cell communication analysis further elucidated epithelial-macrophage crosstalk via MIF and IFN-II signaling, suggesting microenvironment-driven progression mechanisms. Conclusions: Collectively, integrating T cell-Related Ubiquitination genes through advanced computational analyses, we established a robust prognostic model for OSCC and identified MNAT1 as a promoter of malignant progression, highlighting its therapeutic potential.

Indexed as

Biomarkers, TumorMachine LearningMouth NeoplasmsSquamous Cell Carcinoma of Head and NeckTumor Suppressor ProteinsCell Line, TumorGene Expression Regulation, NeoplasticHumansPrognosisRNA-SeqSingle-Cell Gene Expression AnalysisT-LymphocytesTumor MicroenvironmentUbiquitinationBiomarkers, TumorTumor Suppressor Proteinsmachine learningMNAT1oral squamous cell carcinomaT cellubiquitination modification

Identifiers

PMID41235252
PMCPMC12605385

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.